Clinical Trial Review
May 2016 | Volume 15 | Issue 5 | Feature | 651 | Copyright © 2016
Clinical Trial Review is a JDD department designed to provide physicians with information on drugs and devices undergoing clinical testing. It is our goal to inform the reader of the status of select drug and device studies relevant to the practice of dermatology before this information is available through standard channels. To participate in or learn more about these and additional trials, visit www.clinicaltrials.gov.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults
Skin cancer is the most common cancer in the United States, with over a million new cases diagnosed yearly. Young adults are increasingly at risk of melanoma. Contributing to the increasing skin cancer risk is the fact that US adolescents have the lowest skin protection rates of all age groups, and also demonstrate increased exposure to natural and artificial ultraviolet (UV) radiation. Innovative interventions are needed to have an impact on skin cancer risk among young people.
Unlike previous interventions, this skin cancer risk reduction intervention will be tailored to each individual participant and delivered via the Internet. The intervention will emphasize appearance concerns, which are known to be the primary motivation for UV exposure and lack of skin protection among young adults. This will be accomplished in part through the use of personalized facial images showing UV damage, as well as computerized age progression demonstrations.
The primary aim is to examine the efficacy of a tailored intervention delivered via the Internet designed to increase skin protection and decrease sun exposure behavior among young adults at moderate to high risk of developing skin cancer. Participants will be randomized to the tailored intervention, the Skin Cancer Foundation website, or an assessment-only condition.
Reducing Skin Cancer Risk in Childhood Cancer Survivors
The objective of this study is to determine the impact of a 12-month patient activation and education intervention on skin cancer early detection practices among childhood cancer survivors treated with radiation.
There are currently more than 420,000 Americans who are long-term survivors of childhood and adolescent cancer. While these groups have greatly benefited from recent medical advances, primarily increasing overall survival rates, treatment advances have come at a cost. It is now clear that childhood radiation therapy has caused survivors to be at extremely high risk for non-melanoma skin cancer (NMSC) and increased risk of melanoma. Early detection is crucial to reduce the morbidity caused by NMSCs, and the morbidity and mortality incurred due to melanoma. Both patient and provider action are needed to detect and treat early skin cancers and to find new solutions to ensure expedited follow-up care and treatment, especially among those who have little access to dermatologists.
To reduce skin cancers among this young and dispersed patient population, this study will address several key issues: (1) how to provide patients with the skills needed to conduct effective skin self-examinations; (2) how to prompt action from patient’s physicians when worrisome moles and lesions are found; and (3) how to ensure rapid access to dermatologic exams.
Topical Chemoprevention of Skin Cancer Biomarkers
Biomarkers are molecules found in the body and inside of cells. Some biomarkers are associated with specific diseases, such as skin cancer. In this research study, 2 topical medications -- diclofenac and α-difluoromethylornithine (DFMO) -- will be evaluated to test how well they prevent the development of non-melanoma skin cancers by reversing certain biomarkers in the skin.
Twenty-four male and female patients of the Dermatology Clinic at the University of Alabama at Birmingham with a history of basal cell or squamous cell carcinoma of the skin and at least 8 actinic keratoses on the upper extremities are potentially eligible for study participation.
The purpose of the study is to see if diclofenac and DFMO can be applied daily or if they need to be applied twice per day